ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY

Bibliographic Details
Main Authors:	Griesenbach, U, Inoue, M, Meng, C, Farley, R, Chan, M, Newman, N, Brum, A, Kerton, A, Shoemark, A, Boyd, C, Davies, J, Higgins, T, Gill, DR, Hyde, S, Innes, A, Porteous, D, Hasegawa, M, Alton, E
Format:	Journal article
Published:	2012

Similar Items

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
by: Griesenbach, U, et al.
Published: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
by: Griesenbach, U, et al.
Published: (2012)

Towards a first-in-human trial with a pseudotyped lentivirus
by: Alton, EW, et al.
Published: (2020)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
by: Hyde, S, et al.
Published: (2015)

Low levels of CFTR gene transfer with F/HN pseudotyped lentivirus are sufficient to generate ion transport correction in airway cell cultures from cystic fibrosis patients
by: Sergijenko, A, et al.
Published: (2020)

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
by: Griesenbach, U, et al.
Published: (2016)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
by: Pytel, K, et al.
Published: (2016)

Production of transgenic pigs mediated by pseudotyped lentivirus and sperm.
by: Yongliang Zhang, et al.
Published: (2012-01-01)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
by: Davies, J, et al.
Published: (2009)

Lentivirus gene therapy for autoimmune pulmonary alveolar proteinosis
by: Palau, H, et al.
Published: (2019)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
by: Davies, J, et al.
Published: (2009)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY
by: Alton, E, et al.
Published: (2010)

Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
by: Lund-Palau, H, et al.
Published: (2018)

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
by: Alton, E, et al.
Published: (2016)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
by: Alton, E, et al.
Published: (2013)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
by: Alton, E, et al.
Published: (2013)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
by: Davies, G, et al.
Published: (2011)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
by: Davies, J, et al.
Published: (2011)

A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF
by: Alton, E, et al.
Published: (2013)

Lentivirus GM-CSF gene therapy ameliorates autoimmune pulmonary alveolar proteinosis
by: Lund-Palau, H, et al.
Published: (2018)

Lentiviral vector pseudotyped with sendai virus F and HN proteins uses sialylated glycan receptors to efficiently target human airway cells
by: Munday, RJ, et al.
Published: (2020)

F/HN pseudotyped lentiviral vector uses alpha 2,3 sialylated N-acetyllactosamine to efficiently transduce human airway cells
by: Munday, RJ, et al.
Published: (2022)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS: THE RUN-IN STUDY
by: Alton, E, et al.
Published: (2010)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
by: Alton, E, et al.
Published: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
by: Alton, E, et al.
Published: (2012)

Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors
by: Rosie J. Munday, et al.
Published: (2022-09-01)

Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors
by: Munday, RJ, et al.
Published: (2022)

Self-reactive CFTR T cells in humans: implications for gene therapy.
by: Calcedo, R, et al.
Published: (2013)

Genetic medicines for CF: Hype versus reality
by: Alton, E, et al.
Published: (2016)

Assessment of the air-liquid interface culture model as a tool to validate efficacy of a rSIV.F/HN-CFTR vector
by: Sergijenko, A, et al.
Published: (2021)

Transgenesis and Genome Editing of Mouse Spermatogonial Stem Cells by Lentivirus Pseudotyped with Sendai Virus F Protein
by: Takashi Shinohara, et al.
Published: (2020-03-01)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
by: Alton, E, et al.
Published: (2012)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
by: Alton, E, et al.
Published: (2012)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
by: Griesenbach, U, et al.
Published: (2011)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
by: Alton, E, et al.
Published: (2012)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
by: Alton, E, et al.
Published: (2014)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
by: Alton, E, et al.
Published: (2014)

Design and Development of a Pseudotyped-lentivirus for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
by: Hadi Hassannia, et al.
Published: (2023-11-01)

Assessment of selected media supplements to improve F/HN lentiviral vector production yields
by: Gélinas, J, et al.
Published: (2017)

Use of pseudotyped, replication deficient influenza to facilitate testing of gene delivery strategies for treatment of highly infectious diseases
by: Tan, T, et al.
Published: (2018)